{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:17:20Z","timestamp":1787242640584,"version":"build-2736575974"},"reference-count":29,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"European Union Horizon 2020 research and innovation program","award":["634886"],"award-info":[{"award-number":["634886"]}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1136\/ard-2023-223977","type":"journal-article","created":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T13:20:25Z","timestamp":1691155225000},"page":"1307-1314","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Three-month tapering and discontinuation of long- term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: placebo-controlled double blind tapering after the GLORIA trial"],"prefix":"10.1016","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9520-2101","authenticated-orcid":false,"given":"Abdullah Ali Hadi","family":"Almayali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6969-283X","authenticated-orcid":false,"given":"Maarten","family":"Boers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4583-962X","authenticated-orcid":false,"given":"Linda","family":"Hartman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Opris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Bos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2394-6926","authenticated-orcid":false,"given":"Marc R","family":"Kok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2782-6780","authenticated-orcid":false,"given":"Jose AP","family":"Da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ed","family":"Griep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Klaasen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia F","family":"Allaart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Baudoin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hennie G","family":"Raterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7794-6844","authenticated-orcid":false,"given":"Zoltan","family":"Szekanecz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2534-550X","authenticated-orcid":false,"given":"Frank","family":"Buttgereit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavol","family":"Masaryk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6885-3953","authenticated-orcid":false,"given":"Willem","family":"Lems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvo","family":"Smulders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5396-0932","authenticated-orcid":false,"given":"Maurizio","family":"Cutolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke M","family":"ter Wee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2023-223977_bib1","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"10.1136\/ard-2023-223977_bib2","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","article-title":"Rheumatoid arthritis","volume":"376","author":"Scott","year":"2010","journal-title":"Lancet"},{"key":"10.1136\/ard-2023-223977_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000536","article-title":"Glucocorticoids in rheumatoid arthritis: current status and future studies","volume":"6","author":"Hua","year":"2020","journal-title":"RMD Open"},{"key":"10.1136\/ard-2023-223977_bib4","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/art.21747","article-title":"The effect of therapeutic glucocorticoids on the adrenal response in a randomized controlled trial in patients with rheumatoid arthritis","volume":"54","author":"Kirwan","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-223977_bib5","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0140-6736(20)30761-3","article-title":"Tapering glucocorticoids in rheumatoid arthritis","volume":"396","author":"Volkmann","year":"2020","journal-title":"Lancet"},{"key":"10.1136\/ard-2023-223977_bib6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/RHU.0000000000000917","article-title":"Corticosteroid tapering regimens in rheumatic disease: a systematic review","volume":"26","author":"Campbell","year":"2020","journal-title":"J Clin Rheumatol"},{"key":"10.1136\/ard-2023-223977_bib7","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1136\/annrheumdis-2022-222339","article-title":"Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease","volume":"81","author":"Wiebe","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223977_bib8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223977_bib9","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying Antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223977_bib10","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.41752","article-title":"American college of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-223977_bib11","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.3899\/jrheum.130019","article-title":"We still don't know how to taper glucocorticoids in rheumatoid arthritis, and we can do better","volume":"40","author":"Volkmann","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2023-223977_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000225","article-title":"Identifying flares in rheumatoid arthritis: reliability and construct validation of the OMERACT RA flare core domain set","volume":"2","author":"Bykerk","year":"2016","journal-title":"RMD Open"},{"key":"10.1136\/ard-2023-223977_bib13","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.semarthrit.2016.03.001","article-title":"Systemic glucocorticoid therapy and adrenal insufficiency in adults: a systematic review","volume":"46","author":"Joseph","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2023-223977_bib14","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1136\/annrheumdis-2019-216009","article-title":"Evidence to support or guide glucocorticoid tapering in rheumatoid arthritis is lacking","volume":"78","author":"Wallace","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223977_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2021.105285","article-title":"How to taper glucocorticoids in inflammatory rheumatic diseases? A narrative review of novel evidence in rheumatoid arthritis, systemic lupus erythematosus, and giant cell arteritis","volume":"89","author":"Buttgereit","year":"2022","journal-title":"Joint Bone Spine"},{"key":"10.1136\/ard-2023-223977_bib16","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1136\/annrheumdis-2021-221957","article-title":"Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial","volume":"81","author":"Boers","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223977_bib17","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-223977_bib18","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"Rheumatoid arthritis classification criteria: an American college of rheumatology\/European League against rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis & Rheumatism"},{"key":"10.1136\/ard-2023-223977_bib19","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/S0140-6736(13)61684-0","article-title":"Adrenal insufficiency","volume":"383","author":"Charmandari","year":"2014","journal-title":"Lancet"},{"key":"10.1136\/ard-2023-223977_bib20","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S2213-8587(14)70142-1","article-title":"Diagnosis and management of adrenal insufficiency","volume":"3","author":"Bancos","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1136\/ard-2023-223977_bib21","first-page":"201","article-title":"MDHAQ\/Rapid3 scores: quantitative patient history data in a standardized \u201cscientific\u201d format for optimal assessment of patient status and quality of care in rheumatic diseases","volume":"69","author":"Pincus","year":"2011","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"10.1136\/ard-2023-223977_bib22","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(21)00136-7","article-title":"Adrenal insufficiency","volume":"397","author":"Husebye","year":"2021","journal-title":"Lancet"},{"key":"10.1136\/ard-2023-223977_bib23","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0140-6736(20)30636-X","article-title":"Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, Multicentre, randomised controlled trial","volume":"396","author":"Burmester","year":"2020","journal-title":"Lancet"},{"key":"10.1136\/ard-2023-223977_bib24","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(97)01300-7","article-title":"Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis","volume":"350","author":"Boers","year":"1997","journal-title":"Lancet"},{"key":"10.1136\/ard-2023-223977_bib25","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1002\/art.21405","article-title":"Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the best study): a randomized, controlled trial","volume":"52","author":"Goekoop-Ruiterman","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-223977_bib26","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/annrheumdis-2022-eular.868","article-title":"Op0058 certolizumab-pegol, abatacept, tocilizumab or active conventional therapy in early rheumatoid arthritis: clinical and radiographic 48-weeks results of the investigator-initiated randomized Nord-star trial","volume":"81","author":"\u00d8stergaard","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-223977_bib27","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/0002-9343(93)90277-V","article-title":"Recovery of the hypothalamic-pituitary-adrenal (HPA) axis in patients with rheumatic diseases receiving low-dose prednisone","volume":"95","author":"LaRochelle","year":"1993","journal-title":"Am J Med"},{"key":"10.1136\/ard-2023-223977_bib28","doi-asserted-by":"crossref","first-page":"11","DOI":"10.7326\/0003-4819-61-1-11","article-title":"Probabilities of pituitary-adrenal responsiveness after steroid therapy","volume":"61","author":"Danowski","year":"1964","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard-2023-223977_bib29","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/ard.26.1.18","article-title":"Pituitary adrenal function during corticosteroid withdrawal in rheumatoid arthritis","volume":"26","author":"Daly","year":"1967","journal-title":"Ann Rheum Dis"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724102920?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724102920?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2023-223977","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:04:02Z","timestamp":1737331442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724102920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0003496724102920"],"URL":"https:\/\/doi.org\/10.1136\/ard-2023-223977","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Three-month tapering and discontinuation of long- term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: placebo-controlled double blind tapering after the GLORIA trial","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2023-223977","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 \u00a9 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}